Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma

BACKGROUND AND PURPOSE: Glioblastoma is a common primary brain tumor with a poor but variable prognosis. Our aim was to investigate the feasibility of MR perfusion imaging by using arterial spin-labeling for determining the prognosis of patients with glioblastoma. MATERIALS AND METHODS: Pseudocontinuous arterial spin-labeling with 3D background-suppressed gradient and spin-echo was acquired before surgery on 53 patients subsequently diagnosed with glioblastoma. The calculated CBF color maps were visually evaluated by 3 independent readers blinded to patient history. Pathologic and survival data were correlated with CBF map findings. Arterial spin-labeling values in tumor tissue were also quantified by using manual fixed-size ROIs. RESULTS: Two perfusion patterns were characterized by visual evaluation of CBF maps on the basis of either the presence (pattern 1) or absence (pattern 2) of substantial hyperperfused tumor tissue. Evaluation of the perfusion patterns was highly concordant among the 3 readers (κ = 0.898, P < .001). Pattern 1 (versus pattern 2) was associated with significantly shorter progression-free survival by Kaplan-Meier analysis (median progression-free survival of 182 days versus 485 days, P < .01) and trended with shorter overall survival (P = .079). There was a significant association between pattern 1 and epidermal growth factor receptor variant III expression (P < .01). CONCLUSIONS: Qualitative evaluation of arterial spin-labeling CBF maps can be used to stratify survival and predict epidermal growth factor receptor variant III expression in patients with glioblastoma.

[1]  G. Zaharchuk,et al.  Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. , 2015, Magnetic resonance in medicine.

[2]  R. Pallini,et al.  Is deferred use of bevacizumab for glioblastoma associated with prolonged survival? , 2014, Neuro-oncology.

[3]  W. Mueller,et al.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.

[4]  Seung Hong Choi,et al.  Grading of Cerebral Glioma with Multiparametric MR Imaging and 18F-FDG-PET: Concordance and Accuracy , 2014, European Radiology.

[5]  Maria I. Argyropoulou,et al.  Correlation of diffusion tensor, dynamic susceptibility contrast MRI and 99mTc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma , 2014, Clinical Neurology and Neurosurgery.

[6]  Whitney B. Pope,et al.  Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke — Comparison with dynamic susceptibility contrast enhanced perfusion imaging☆ , 2013, NeuroImage: Clinical.

[7]  P. LaViolette,et al.  Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. , 2013, Neuro-oncology.

[8]  Ryan A. Grant,et al.  Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. , 2012, Neuro-oncology.

[9]  Whitney B. Pope,et al.  The Value of Arterial Spin-Labeled Perfusion Imaging in Acute Ischemic Stroke: Comparison With Dynamic Susceptibility Contrast-Enhanced MRI , 2012, Stroke.

[10]  J. Debbins,et al.  Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma , 2012, American Journal of Neuroradiology.

[11]  Bram Stieltjes,et al.  Biopsy Targeting Gliomas: Do Functional Imaging Techniques Identify Similar Target Areas? , 2010, Investigative radiology.

[12]  Erwin G. Van Meir,et al.  Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma , 2010, CA: a cancer journal for clinicians.

[13]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Kaye,et al.  The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.

[15]  H. R. Arvinda,et al.  Retraction Note to: Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging , 2009, Journal of Neuro-Oncology.

[16]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[17]  T Sasaki,et al.  Perfusion Imaging of Brain Tumors Using Arterial Spin-Labeling: Correlation with Histopathologic Vascular Density , 2008, American Journal of Neuroradiology.

[18]  S. Horvath,et al.  Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples , 2008, Clinical Cancer Research.

[19]  E. Melhem,et al.  Arterial Spin-Labeling and MR Spectroscopy in the Differentiation of Gliomas , 2007, American Journal of Neuroradiology.

[20]  S. Y. Kim,et al.  A Prospective Study on the Added Value of Pulsed Arterial Spin-Labeling and Apparent Diffusion Coefficients in the Grading of Gliomas , 2007, American Journal of Neuroradiology.

[21]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[22]  Li Zhang,et al.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[24]  J. Raizer HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme , 2005, Journal of Neuro-Oncology.

[25]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[26]  D. O’Rourke,et al.  SHP-2-Dependent Mitogen-Activated Protein Kinase Activation Regulates EGFRvIII but not Wild-Type Epidermal Growth Factor Receptor Phosphorylation and Glioblastoma Cell Survival , 2004, Cancer Research.

[27]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[28]  Joseph A Maldjian,et al.  Arterial transit time imaging with flow encoding arterial spin tagging (FEAST) , 2003, Magnetic resonance in medicine.

[29]  C. Zimmer,et al.  Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. , 2003, Radiology.

[30]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[31]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[32]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Cloughesy,et al.  Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. , 2014, Neuro-oncology.

[34]  S. Ekholm,et al.  Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes , 2013, Journal of Neuro-Oncology.

[35]  Mei-Yin Polley,et al.  Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.

[36]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.